Abstract

*Dr. Sushil Rana, Dr. Deep Narayan Sharma, Sahil Chandel and Abhishek Jain

ABSTRACT

The development of liposomal drug Formulations has revolutionized oncological therapeutics, offering targeted and controlled delivery systems that enhance efficacy while reducing systemic toxicity to the patients. Present research explores the innovative methodologies of Liposomal Doxorubicin. Hydrochloride employed by Biozenta Lifesciences Pvt. Ltd. a leading pharmaceutical enterprise renowned for its high-quality oncology formulations. One of the company's landmark innovations is the development of liposomal Doxorubicin, a chemotherapy drug encapsulated in lipid bilayers to improve pharmacokinetics. bioavailability, and patient outcomes. This formulation leverages advanced nanotechnology to encapsulate Doxorubicin, achieving remarkable drng stability and enhanced delivery to tumor sites via passive and active targeting mechanisms. The liposomal design minimizes cardio toxicity and myelosuppression, common adverse effects of traditional Doxorubicin therapy, while improving therapeutic efficacy. The Liposome formation was fixed by employing cutting-edge techniques such as high-resolution transmission electron microscopy (HR-TEM). dynamic light scattering, and HPLC analysis to confirm the particle lamellarity, size uniformity. and drug entrapment efficiency, achieving an impressive 98% encapsulation rate with nanoscale size (314.16 nm) and stable zeta potential (-0.5 mV) of the liposomes ensure effective tumor penetration and prolonged circulation time, enhancing drug efficacy.